Sign In
Buy GUTS
$0.760
-0.0297 (-3.76%)
At Close: Jun 03, 2026
At DDG, Fractyl Health will present new clinical updates on its ongoing real-world registry study of Revita ® in patients with T2D in Germany At DDW, Fractyl Health will provide an oral presentation
The 3 Most Volatile Stocks for Short-Term Traders: April 2024
03:10pm, Wednesday, 17'th Apr 2024
Volatile stocks are short-term traders' bread and butter. Making money both ways – whether the stock goes up or down – means that finding the most volatile stocks is the shortest path to fast cash
BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for the treatment o
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
07:00am, Monday, 01'st Apr 2024
Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-
Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)
08:08am, Tuesday, 19'th Mar 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
Fractyl Health today announced promising new preclinical findings for the first clinical candidate in its Rejuva® pancreatic gene therapy platform.
LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (“Fractyl Health” or the “Company”), a metabolic therapeutics company focused on pioneering new approach
Another Huge Buffett Purchase Highlights Recent Insider Buying
08:53am, Monday, 12'th Feb 2024
The most notable of insider purchases in the past week or so is again legendary investor Warren Buffett boosting the Berkshire Hathaway stake in his favorite petroleum company.
U.S. IPO Weekly Recap: Amer Sports' Billion-Dollar U.S. IPO Leads A Week Of Large Listings
06:16am, Sunday, 04'th Feb 2024
Sports equipment and apparel maker Amer Sports priced below the range to raise $1.3 billion at a $6.4 billion market cap. CNS disorder biotech Alto Neuroscience priced its upsized IPO at the top of th
Fractyl Health valued at $654.6 mln in tepid debut
01:44pm, Friday, 02'nd Feb 2024
Shares of Fractyl Health fell 8.3% on their market debut on Friday, giving the obesity and diabetes drug developer a market capitalization of $654.6 million.
Fractyl Health prices US IPO below range to raise $110 mln
09:39pm, Thursday, 01'st Feb 2024
Obesity and diabetes drug developer Fractyl Health on Thursday priced its U.S. initial public offering (IPO) below an indicated range to raise $110 million.
Fractyl Health Announces Pricing of Initial Public Offering
08:08pm, Thursday, 01'st Feb 2024
LEXINGTON, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and
GUTS IPO News: 5 Things to Know as Fractyl Health Plans to Go Public
02:29pm, Tuesday, 30'th Jan 2024
Thus far, 2024 has been a mixed year for initial public offerings (IPOs). Various IPOs in 2023 performed well, but many underperformed expectations.
